Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
NCT03075826Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2016
- Primary completion
- Mar 2021
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of guadecitabine in myeloproliferative neoplasms (MPN), sponsored by Weill Cornell Medicine. Started Mar 2016; status: completed.
02
Drugs
guadecitabine
03
Conditions
myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT03075826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075826.